BR112014029108B1 - Composições que compreendem benzodiazepinas de curta ação, uso de uma mistura de pelo menos um dissacarídeo e pelo menos uma dextrana e método de preparação de uma composição farmacêutica - Google Patents

Composições que compreendem benzodiazepinas de curta ação, uso de uma mistura de pelo menos um dissacarídeo e pelo menos uma dextrana e método de preparação de uma composição farmacêutica Download PDF

Info

Publication number
BR112014029108B1
BR112014029108B1 BR112014029108-0A BR112014029108A BR112014029108B1 BR 112014029108 B1 BR112014029108 B1 BR 112014029108B1 BR 112014029108 A BR112014029108 A BR 112014029108A BR 112014029108 B1 BR112014029108 B1 BR 112014029108B1
Authority
BR
Brazil
Prior art keywords
composition
dextran
cns
lyophilized
lactose
Prior art date
Application number
BR112014029108-0A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014029108A2 (pt
Inventor
John Aitken Graham
Alan James Baillie
Kevin Richard Ward
Thomas Peacock
Original Assignee
Paion Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48669863&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014029108(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Paion Uk Limited filed Critical Paion Uk Limited
Publication of BR112014029108A2 publication Critical patent/BR112014029108A2/pt
Publication of BR112014029108B1 publication Critical patent/BR112014029108B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112014029108-0A 2012-05-22 2013-05-22 Composições que compreendem benzodiazepinas de curta ação, uso de uma mistura de pelo menos um dissacarídeo e pelo menos uma dextrana e método de preparação de uma composição farmacêutica BR112014029108B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12168968.1 2012-05-22
EP12168968 2012-05-22
PCT/EP2013/060543 WO2013174883A1 (en) 2012-05-22 2013-05-22 Compositions comprising short-acting benzodiazepines

Publications (2)

Publication Number Publication Date
BR112014029108A2 BR112014029108A2 (pt) 2017-06-27
BR112014029108B1 true BR112014029108B1 (pt) 2022-02-08

Family

ID=48669863

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014029108-0A BR112014029108B1 (pt) 2012-05-22 2013-05-22 Composições que compreendem benzodiazepinas de curta ação, uso de uma mistura de pelo menos um dissacarídeo e pelo menos uma dextrana e método de preparação de uma composição farmacêutica

Country Status (41)

Country Link
US (2) US20150148338A1 (https=)
EP (1) EP2852389B1 (https=)
JP (1) JP6313286B2 (https=)
KR (1) KR102116737B1 (https=)
CN (2) CN108578413A (https=)
AP (1) AP2014008084A0 (https=)
AR (1) AR092008A1 (https=)
AU (1) AU2013265295B2 (https=)
BR (1) BR112014029108B1 (https=)
CA (1) CA2874247C (https=)
CL (1) CL2014003171A1 (https=)
CO (1) CO7151503A2 (https=)
DK (1) DK2852389T3 (https=)
EA (1) EA032119B1 (https=)
EC (1) ECSP14032553A (https=)
ES (1) ES2651389T3 (https=)
FR (1) FR21C1043I2 (https=)
GE (2) GEAP201813666A (https=)
HR (1) HRP20171872T1 (https=)
HU (2) HUE037734T2 (https=)
IL (1) IL235789B (https=)
LT (2) LT2852389T (https=)
LU (1) LUC00230I2 (https=)
MA (1) MA37581B1 (https=)
MX (1) MX368854B (https=)
MY (1) MY185117A (https=)
NL (1) NL301130I2 (https=)
NO (2) NO2852389T3 (https=)
NZ (1) NZ702063A (https=)
PE (1) PE20150683A1 (https=)
PH (1) PH12014502608B1 (https=)
PL (1) PL2852389T4 (https=)
PT (1) PT2852389T (https=)
RS (1) RS56660B1 (https=)
SG (1) SG11201407710VA (https=)
SI (1) SI2852389T1 (https=)
TN (1) TN2014000479A1 (https=)
TW (1) TWI590826B (https=)
UA (1) UA115063C2 (https=)
WO (1) WO2013174883A1 (https=)
ZA (1) ZA201408412B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2657347C (en) 2006-07-10 2014-11-18 Paion Uk Limited Short-acting benzodiazepine salts and their polymorphic forms
EP2305647A1 (en) 2009-09-18 2011-04-06 PAION UK Limited Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
WO2015076340A1 (ja) * 2013-11-21 2015-05-28 小野薬品工業株式会社 全身麻酔および／または鎮静のための注射用組成物
ES2958606T3 (es) 2014-02-10 2024-02-12 Biolumic Ltd Mejoras en y relacionadas con el control de características de organismos fotosintéticos
JP6697806B2 (ja) 2014-03-14 2020-05-27 バイオルミック リミテッド 作物の収量及び／又は品質を改善する方法
HUE047450T2 (hu) 2014-07-23 2020-04-28 Jiangsu Nhwaluokang Pharmaceutical Res And Development Co Ltd Új benzodiazepin származék és alkalmazása
EP4091440A1 (en) 2014-09-17 2022-11-23 Biolumic Limited Method of seed treatments and resulting products
CN105726495B (zh) * 2014-12-12 2019-03-29 宜昌人福药业有限责任公司 一种注射用短效苯并二氮杂卓盐药物组合物及其制备方法
CN107198691A (zh) * 2016-03-17 2017-09-26 江苏恒瑞医药股份有限公司 一种瑞马唑仑的药物组合物
EP3442539B1 (en) * 2016-04-14 2025-04-09 Paion UK Limited Orally inhaled and nasal benzodiazepines
CN108289897B (zh) * 2016-05-20 2020-07-28 江苏恒瑞医药股份有限公司 一种瑞马唑仑的药物组合物
CA3034739A1 (en) 2016-08-22 2018-03-01 Biolumic Limited System, device and methods of seed treatment
CN108503644B (zh) 2016-12-09 2019-06-14 成都倍特药业有限公司 一种苯并二氮杂*衍生物的氢溴酸盐及其制备方法和用途
WO2019002946A1 (en) 2017-06-29 2019-01-03 Biolumic Limited METHOD OF ENHANCING YIELD AND / OR CULTURE QUALITY
EP3714884A1 (en) 2019-03-27 2020-09-30 Paion UK Limited Medical uses for benzodiazepines with a particular eeg pattern
CN112209932B (zh) * 2019-07-12 2023-03-24 成都倍特药业股份有限公司 一种化合物氢溴酸盐的新固体形态及其制备方法和用途
ES2803099B2 (es) * 2019-07-22 2021-11-08 Moehs Iberica Sl Procedimiento de obtención de besilato de remimazolam amorfo
CN114478535B (zh) * 2020-10-23 2024-02-09 成都苑东生物制药股份有限公司 一种苯磺酸瑞马唑仑ii晶型的制备方法
CN112462015B (zh) * 2020-11-18 2022-07-12 海南倍特药业有限公司 一种氢溴酸瑞马唑仑细菌内毒素的检测方法
CN114624351B (zh) * 2020-12-14 2024-04-09 宜昌人福药业有限责任公司 苯磺酸瑞马唑仑原料药中(r)-(-)-1-氨基-2-丙醇残留的分析方法
AU2023394304A1 (en) * 2022-12-16 2025-05-22 Lts Lohmann Therapie-Systeme Ag Oromucosal delivery system containing remimazolam
EP4711368A1 (en) * 2023-06-09 2026-03-18 Chengdu Mfs Pharma. Co., Ltd. Azepine compound, and composition and use thereof
WO2025052259A1 (en) 2023-09-05 2025-03-13 Reena Patel Ready to use compositions of remimazolam

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3520877A (en) * 1967-10-02 1970-07-21 Hoffmann La Roche 3-carbonyl amino acetic acid ethyl ester substituted benzodiazepines
CA2143246C (en) 1994-03-16 2000-08-22 Thierry Godel Imidazodiazepines
PT801651E (pt) 1995-01-06 2001-12-28 Hoffmann La Roche Hidroximetil-imidazodiazepinas e seus esteres
AU4382896A (en) 1995-02-02 1996-08-21 F. Hoffmann-La Roche Ag Acetylimidazobenzodiazepines
JPH0971533A (ja) * 1995-06-30 1997-03-18 Takeda Chem Ind Ltd 凍結乾燥製剤
GB9911152D0 (en) * 1999-05-14 1999-07-14 Glaxo Group Ltd Short-acting benzodiazepines
US7160880B1 (en) * 1999-05-14 2007-01-09 Cenes Limited Short-acting benzodiazepines
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
EP1161949A1 (en) * 2000-06-09 2001-12-12 Warner-Lambert Company Use od diazepinoindoles for the treatment of chronic obstructive pulmonary disease
MX2007009915A (es) * 2005-02-15 2007-11-06 Elan Pharma Int Ltd Formulaciones en aerosol e inyectables de benzodiazepina nanoparticulada.
GB0613692D0 (en) * 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts
CA2657347C (en) * 2006-07-10 2014-11-18 Paion Uk Limited Short-acting benzodiazepine salts and their polymorphic forms
GB0613693D0 (en) * 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts (3)
CN101352422B (zh) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 河豚毒素冻干粉针制剂及其制备方法
RS54645B1 (sr) * 2009-11-05 2016-08-31 Glaxosmithkline Llc Benzodiazepin kao inhibitor bromodomena
EP2450039A1 (en) * 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
CN102964349A (zh) * 2011-08-31 2013-03-13 江苏恒瑞医药股份有限公司 苯并二氮杂*衍生物的托西酸盐及其多晶型、它们的制备方法和用途

Also Published As

Publication number Publication date
KR102116737B1 (ko) 2020-05-29
DK2852389T3 (en) 2017-12-18
GEAP201813666A (en) 2018-01-25
JP6313286B2 (ja) 2018-04-18
HUE037734T2 (hu) 2018-09-28
EA032119B1 (ru) 2019-04-30
NO2021041I1 (no) 2021-09-20
US20220040198A1 (en) 2022-02-10
WO2013174883A1 (en) 2013-11-28
LT2852389T (lt) 2017-12-27
RS56660B1 (sr) 2018-03-30
HRP20171872T1 (hr) 2018-02-23
PT2852389T (pt) 2017-12-13
AP2014008084A0 (en) 2014-11-30
CL2014003171A1 (es) 2015-06-19
AR092008A1 (es) 2015-03-18
SG11201407710VA (en) 2015-01-29
SI2852389T1 (en) 2018-02-28
LTC2852389I2 (https=) 2024-11-25
MA37581B1 (fr) 2016-07-29
CN108578413A (zh) 2018-09-28
AU2013265295A1 (en) 2015-01-22
IL235789A0 (en) 2015-01-29
PH12014502608A1 (en) 2015-01-21
TWI590826B (zh) 2017-07-11
JP2015517552A (ja) 2015-06-22
KR20150009601A (ko) 2015-01-26
EP2852389B1 (en) 2017-10-18
US20150148338A1 (en) 2015-05-28
CA2874247C (en) 2020-07-28
NO2852389T3 (https=) 2018-03-17
MX368854B (es) 2019-10-18
FR21C1043I2 (fr) 2022-10-07
LTPA2021521I1 (https=) 2021-10-11
PH12014502608B1 (en) 2019-11-27
EA201492160A1 (ru) 2015-10-30
IL235789B (en) 2019-07-31
UA115063C2 (uk) 2017-09-11
ZA201408412B (en) 2016-09-28
ECSP14032553A (es) 2018-11-30
PE20150683A1 (es) 2015-06-03
EP2852389A1 (en) 2015-04-01
TW201400119A (zh) 2014-01-01
HUS2100040I1 (hu) 2021-10-28
LUC00230I2 (https=) 2022-10-07
GEP20186852B (en) 2018-05-25
NL301130I2 (nl) 2021-10-25
CO7151503A2 (es) 2014-12-29
MX2014014225A (es) 2015-06-17
PL2852389T3 (pl) 2018-02-28
CA2874247A1 (en) 2013-11-28
CN104968348B (zh) 2018-04-17
HK1208164A1 (en) 2016-02-26
TN2014000479A1 (en) 2016-03-30
FR21C1043I1 (https=) 2021-11-19
MY185117A (en) 2021-04-30
NL301130I1 (https=) 2021-09-22
BR112014029108A2 (pt) 2017-06-27
MA20150233A1 (fr) 2015-07-31
NZ702063A (en) 2016-11-25
AU2013265295B2 (en) 2017-08-31
ES2651389T3 (es) 2018-01-26
PL2852389T4 (pl) 2022-02-21
CN104968348A (zh) 2015-10-07

Similar Documents

Publication Publication Date Title
BR112014029108B1 (pt) Composições que compreendem benzodiazepinas de curta ação, uso de uma mistura de pelo menos um dissacarídeo e pelo menos uma dextrana e método de preparação de uma composição farmacêutica
JP5536753B2 (ja) ベンダムスチン塩酸塩の新規固体形態
TW202019934A (zh) 包含parp抑制劑的藥物組合物
CN101444510B (zh) 含有伏立康唑的药物制剂及其制备方法
ES2573982T3 (es) Proceso para la producción de coevaporados y complejos que comprenden voriconazol y ciclodextrina
BRPI0517238B1 (pt) Composições que compreendem ecteinascidina e um dissacarídeo, método para produzir um frasco que contém a referida composição e para preparar uma solução para infusão intravenosa e uso da referida solução
BR112012009660B1 (pt) lipossoma tendo fase de água interna contendo sal de ciclodextrina de éter sulfobutílico, seu processo de preparação, seu uso e preparação farmacêutica lipossômica
BR112015005400B1 (pt) Formulação de daptomicina liofilizada, formulação de daptomicina reconstituída, método para tratar um biofilme e método para preparar uma formulação de daptomicina liofilizada
Zhao et al. Amorphous solid dispersions of glycyrrhetinic acid: using soluplus, PVP, and PVPVA as the polymer matrix to enhance solubility, bioavailability, and stability
Liu et al. Preparation, characterization and evaluation of nintedanib amorphous solid dispersions with enhanced oral bioavailability
CN108289897B (zh) 一种瑞马唑仑的药物组合物
CA2894935A1 (en) Novel crystalline forms of ceftaroline fosamil
HK1208164B (en) Compositions comprising short-acting benzodiazepines
US20140206874A1 (en) Crystal form i of salt of a dipeptidyl peptidase-iv inhibitor and preparation method and use same
OA20108A (en) Compositions Comprising Short-Acting Benzodiazepines.
WO2025162373A1 (en) Electrophile-containing catechol-o-methyltransferase (comt) inhibitors for targeting the keap1/nrf2 pathway
ES2964602T3 (es) Liofilizado de treosulfano
Shahe et al. Compatibility studies between propafenone and selected excipients used in the development of controlled release formulations
BR102023017927A2 (pt) Cocristal de decitabina, processos de obtenção de referido cocristal e uso dos mesmos
BR112015005489B1 (pt) Composição farmacêutica para administração oral com dissolução e/ou absorção aperfeiçoadas
BR112021013764B1 (pt) Método de preparação de uma composição farmacêutica compreendendo acetaminofeno e nefopa
BR112020014292B1 (pt) Formulação farmacêutica tendo grânulos de everolimo, método de produção e uso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/05/2013, OBSERVADAS AS CONDICOES LEGAIS.